396 related articles for article (PubMed ID: 21978456)
21. Vimentin as a poor prognostic factor for triple-negative breast cancer.
Yamashita N; Tokunaga E; Kitao H; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Aishima S; Morita M; Maehara Y
J Cancer Res Clin Oncol; 2013 May; 139(5):739-46. PubMed ID: 23354842
[TBL] [Abstract][Full Text] [Related]
22. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Sabatier R; Finetti P; Guille A; Adelaide J; Chaffanet M; Viens P; Birnbaum D; Bertucci F
Mol Cancer; 2014 Oct; 13():228. PubMed ID: 25277734
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer.
Al-Ejeh F; Simpson PT; Sanus JM; Klein K; Kalimutho M; Shi W; Miranda M; Kutasovic J; Raghavendra A; Madore J; Reid L; Krause L; Chenevix-Trench G; Lakhani SR; Khanna KK
Oncogenesis; 2014 Apr; 3(4):e100. PubMed ID: 24752235
[TBL] [Abstract][Full Text] [Related]
24. [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
Svoboda M; Navrátil J; Fabian P; Palácová M; Gombošová J; Slámová L; Princ D; Syptáková B; Kudláček A; Bílek O; Pospíšil P; Kazda T; Grell P; Poprach A; Selingerová I; Nenutil R; Juráček J; Héžová R; Slabý O; Vyzula R
Klin Onkol; 2012; 25(3):188-98. PubMed ID: 22724568
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype.
Wang X; Chao L; Ma G; Chen L; Zang Y; Sun J
J Cancer Res Clin Oncol; 2011 Feb; 137(2):271-8. PubMed ID: 20401669
[TBL] [Abstract][Full Text] [Related]
27. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
Li Y; Yang W; Yang Q; Zhou S
Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
[TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
29. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
30. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.
Iglesia MD; Vincent BG; Parker JS; Hoadley KA; Carey LA; Perou CM; Serody JS
Clin Cancer Res; 2014 Jul; 20(14):3818-29. PubMed ID: 24916698
[TBL] [Abstract][Full Text] [Related]
31. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
32. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G
Breast Cancer Res Treat; 2019 Sep; 177(2):335-343. PubMed ID: 31222709
[TBL] [Abstract][Full Text] [Related]
33. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
37. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
Kuo WH; Chang YY; Lai LC; Tsai MH; Hsiao CK; Chang KJ; Chuang EY
PLoS One; 2012; 7(9):e45831. PubMed ID: 23049873
[TBL] [Abstract][Full Text] [Related]
38. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
39. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
40. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.
Bhardwaj A; Ganesan N; Tachibana K; Rajapakshe K; Albarracin CT; Gunaratne PH; Coarfa C; Bedrosian I
PLoS One; 2015; 10(5):e0127678. PubMed ID: 26000884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
